<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01341639</url>
  </required_header>
  <id_info>
    <org_study_id>V419-007</org_study_id>
    <secondary_id>2010-021490-37</secondary_id>
    <nct_id>NCT01341639</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)</brief_title>
  <official_title>A Phase III Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4, and 12 Months (V419-007-03)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MCM Vaccines B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>MCM Vaccines B.V.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine whether subjects who receive V419 at 2, 3, 4, and 12 months of age
      have an acceptable immune response to the vaccine. The study will also determine whether the
      immune response to V419 is similar to that of subjects who receive a licensed vaccine
      control.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of responders to polyribosylribitol phosphate (PRP) antigen</measure>
    <time_frame>Post-dose 3 (5 Months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of responders to diphtheria antigen</measure>
    <time_frame>Post-dose 3 (5 Months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of responders to tetanus antigen</measure>
    <time_frame>Post-dose 3 (5 Months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of responders to inactivated poliovirus (IPV) antigen</measure>
    <time_frame>Post-dose 3 (5 Months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of responders to polyribosylribitol phosphate (PRP) antigen</measure>
    <time_frame>Post-dose 4 (13 Months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of responders to diphtheria antigen</measure>
    <time_frame>Post-dose 4 (13 Months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of responders to tetanus antigen</measure>
    <time_frame>Post-dose 4 (13 Months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of responders to inactivated poliovirus (IPV) antigen</measure>
    <time_frame>Post-dose 4 (13 Months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of responders to hepatitis B surface antigen (HBsAg)</measure>
    <time_frame>Post-dose 4 (13 Months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of responders to pertussis antigens</measure>
    <time_frame>Post-dose 4 (Month 13)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of responders to measles antigen</measure>
    <time_frame>Post-dose 4 (13 Months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of responders to mumps antigen</measure>
    <time_frame>Post-dose 4 (13 Months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of responders to rubella antigen</measure>
    <time_frame>Post-dose 4 (13 Months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of responders to varicella antigen</measure>
    <time_frame>Post-dose 4 (13 Months)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1250</enrollment>
  <condition>Bacterial Infections</condition>
  <condition>Virus Diseases</condition>
  <arm_group>
    <arm_group_label>V419</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>V419 + RotaTeq + Prevenar 13 + ProQuad</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INFANRIX hexa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>INFANRIX hexa + RotaTeq + Prevenar 13 + ProQuad</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V419</intervention_name>
    <description>V419 (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate [Meningococcal Outer Membrane Protein Complex], and Hepatitis B [Recombinant] Vaccine) 0.5 mL intramuscular injection at 2, 3, 4, and 12 months of age</description>
    <arm_group_label>V419</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>INFANRIX hexa</intervention_name>
    <description>INFANRIX™ hexa 0.5 mL intramuscular injection at 2, 3, 4, and 12 months of age.</description>
    <arm_group_label>INFANRIX hexa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RotaTeq</intervention_name>
    <description>RotaTeq 2 mL oral dose at 2, 3, and 4 months of age</description>
    <arm_group_label>V419</arm_group_label>
    <arm_group_label>INFANRIX hexa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevenar 13</intervention_name>
    <description>Prevenar 13 0.5 mL intramuscular injection at 2, 3, 4,and 13 months of age</description>
    <arm_group_label>V419</arm_group_label>
    <arm_group_label>INFANRIX hexa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ProQuad</intervention_name>
    <description>ProQuad™ 0.5 mL subcutaneous injection at 12 and 13 months of age</description>
    <arm_group_label>V419</arm_group_label>
    <arm_group_label>INFANRIX hexa</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Healthy infants able to attend all study visits

          -  Parent(s)/legal representative able to read, understand, and complete study
             questionnaires

        Exclusion Criteria

          -  History of congenital or acquired immunodeficiency

          -  Received or is expected to receive immunosuppressive agents or systemic
             immunomodulatory steroids

          -  History of leukemia, lymphoma, malignant melanoma, or myeloproliferative disorder

          -  Hypersensitivity to any of the vaccine components or history of a life-threatening
             reaction to a vaccine containing the same substances as the study vaccines or
             concomitant study vaccines

          -  Has any chronic illness that could interfere with study conduct or completion

          -  Received any immune globulin, blood, or blood-derived products since birth

          -  Received a dose of hepatitis B vaccine prior to the study

          -  Vaccinated with any acellular pertussis or whole cell pertussis based combination
             vaccines,Haemophilus influenzae type b conjugate, poliovirus, pneumococcal conjugate
             or pneumococcal polysaccharide, rotavirus, measles, mumps, rubella, or varicella
             vaccines, or any combination thereof

          -  Fever within 24 hours prior to enrollment

          -  Received any non-study vaccine within 30 days prior to enrollment, except for
             inactivated influenza vaccine, which is permitted 14 days or more prior to enrollment

          -  Has a coagulation disorder

          -  Has developmental delay or neurological disorder

          -  Participant or his/her mother has a medical history of hepatitis B surface antigen
             (HBsAg)seropositivity

          -  History of measles, mumps, rubella, varicella, Haemophilus influenzae type B,
             hepatitis B, diphtheria, tetanus, pertussis, rotavirus, invasive pneumococcal, or
             poliomyelitis infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>46 Days</minimum_age>
    <maximum_age>74 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0070001</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0070002</name>
      <address>
        <city>Hasselt</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0070011</name>
      <address>
        <city>Espoo</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0070008</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0070010</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0070006</name>
      <address>
        <city>Jarvenpaa</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0070045</name>
      <address>
        <city>Kokkola</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0070007</name>
      <address>
        <city>Lahti</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0070012</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0070005</name>
      <address>
        <city>Pori</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0070013</name>
      <address>
        <city>Seinajoki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0070003</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0070004</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0070009</name>
      <address>
        <city>Vantaa</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0070051</name>
      <address>
        <city>Aalen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0070016</name>
      <address>
        <city>Alsfeld</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0070036</name>
      <address>
        <city>Aschaffenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0070018</name>
      <address>
        <city>Baunatal</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0070039</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0070015</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0070033</name>
      <address>
        <city>Bonnigheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0070014</name>
      <address>
        <city>Bramsche</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0070029</name>
      <address>
        <city>Bretten</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0070038</name>
      <address>
        <city>Datteln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0070024</name>
      <address>
        <city>Erfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0070048</name>
      <address>
        <city>Fulda</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0070049</name>
      <address>
        <city>Hagen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0070026</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0070020</name>
      <address>
        <city>Herbolzheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0070052</name>
      <address>
        <city>Herford</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0070019</name>
      <address>
        <city>Karlsruhe</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0070041</name>
      <address>
        <city>Kleve-Materborn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0070034</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0070042</name>
      <address>
        <city>Marbach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0070022</name>
      <address>
        <city>Monchengladbach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0070030</name>
      <address>
        <city>Monchengladbach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0070050</name>
      <address>
        <city>Neumunster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0070031</name>
      <address>
        <city>Oberhausen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0070053</name>
      <address>
        <city>Schwäbisch Hall</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0070023</name>
      <address>
        <city>Solingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0070025</name>
      <address>
        <city>Stockelsdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0070035</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0070032</name>
      <address>
        <city>Tuttlingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0070037</name>
      <address>
        <city>Welzheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Finland</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2011</study_first_submitted>
  <study_first_submitted_qc>April 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2011</study_first_posted>
  <last_update_submitted>February 27, 2017</last_update_submitted>
  <last_update_submitted_qc>February 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>combination vaccine</keyword>
  <keyword>diphtheria</keyword>
  <keyword>pertussis</keyword>
  <keyword>tetanus</keyword>
  <keyword>hepatitis B</keyword>
  <keyword>Hep B</keyword>
  <keyword>Haemophilus influenzae b</keyword>
  <keyword>Hib</keyword>
  <keyword>polio</keyword>
  <keyword>poliovirus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

